CD276 (B7-H3) is an immune checkpoint molecule belonging to the B7 family and encodes a type I transmembrane protein. It plays a role in regulating T cell-mediated immune responses. CD276 is highly expressed in various tumor cells and tumor-infiltrating immune cells, aiding tumor cells in evading immune surveillance and promoting tumor proliferation, metastasis, and treatment resistance. Additionally, CD276 is associated with cancer stem cell properties, and its high expression is linked to poor prognosis. Currently, several targeted therapies against CD276, including monoclonal antibodies, bispecific antibodies, antibody-drug conjugates (ADCs), and CAR-T cell therapies, are under development and in clinical trials, showing promising anti-tumor potential.